Resources
About Us
Home Report
Store
Neurogenomics Market
Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering (NGS [Kits {Library Prep, QC, DNA Extraction}, Systems], PCR, Microarrays {Protein, DNA, RNA, Tissue}, Software) Application (Research, Clinical) End User - Global Forecast to 2031
Report ID:MRHC - 1041336 Pages: 250 Oct-2024 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe Neurogenomics Market was valued at $1.37 billion in 2023. This market is expected to reach $4.68 billion by 2031 from an estimated $1.59 billion in 2024, at a CAGR of 16.6% during the forecast period from 2024 to 2031.
Neurogenomics Market Size & Forecast
The growth of the neurogenomics market is driven by several factors, including decreasing sequencing costs, the rising prevalence of neurological disorders, and the increasing adoption of advanced sequencing technologies for disease diagnostics and precision medicine. Additional drivers include increased pharmaceutical R&D expenditures, improvements in regulatory and reimbursement frameworks for gene sequencing, rising healthcare expenditures, and increased funding for research activities. There is also a growing emphasis on early detection and prevention of neurological disorders, along with technological advancements in neurogenomics products and government initiatives that promote the use of sequencing in both clinical and research applications.
However, the high prices of neurogenomics products, the low chances of identifying positive, actionable mutations for precision medicine, and ethical & legal issues related to sequencing-based diagnosis are factors restraining the growth of this market.
Additionally, the increasing adoption of targeted therapies, emerging economies, and rising awareness regarding neurological disorders are expected to generate growth opportunities for market stakeholders. However, the dynamic regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the shortage of sequencing professionals, and the high capital investments required for sequencing setups are major challenges impacting the growth of the neurogenomics market.
Click here to: Get a Free Sample Copy of this report
Neurogenomics Market Growth Drivers
Growing Utilization of Advanced Sequencing Technologies in Disease Diagnostics & Precision Medicine
Precision medicine is an innovative approach to patient care that tailors treatment methods based on an individual's genetic makeup while also accounting for genetic changes related to disease and lifestyle factors. This emerging strategy for disease treatment and prevention recognizes the variability in genes, environments, and lifestyles among individuals. By minimizing guesswork and trial-and-error in medication selection, precision medicine helps physicians address challenges related to variable diagnostic capabilities and develop treatment strategies based on broader demographic insights.
Additionally, precision medicine offers a more comprehensive view of a patient's health. In clinical neurogenomics workflows, it enhances predictive and preventive care through targeted therapies. Key benefits of precision medicine for neurological conditions include reduced reliance on trial-and-error prescriptions, prevention of adverse drug reactions, improved patient adherence to treatment due to fewer side effects, decreased prescriptions for unnecessary medications in non-responder patients, and optimized drug development costs.
Increasing Prevalence of Neurological Disorders
According to The Lancet Neurology’s 2021 report, neurological conditions affected 43% of the global population or approximately 3.4 billion individuals. In that year, these conditions accounted for 443 million years of healthy life lost due to disability, illness, and premature death (measured in disability-adjusted life years), making them the leading contributors to the global disease burden, surpassing cardiovascular diseases. Key contributors to neurological health loss included migraine, neonatal encephalopathy, stroke, diabetic neuropathy, Alzheimer’s disease, and other dementias.
In 2021, pediatric and neurodevelopmental conditions were expected to represent about one-fifth of the total neurological burden globally, equivalent to 80 million years of healthy life lost. Diabetic neuropathy emerged as the fastest-growing neurological condition, with cases more than tripling since 1990, reaching 206 million in 2021, largely due to the global increase in diabetes. Additionally, new conditions such as neurological complications from COVID-19—including cognitive impairment and Guillain-Barré syndrome—now account for over 23 million cases (Source: World Health Organization, March 2024 Report).
In 2021, central and western sub-Saharan Africa were the regions with the highest nervous system burden, while high-income Asia-Pacific and Australasia had the lowest burden. According to a major analysis from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021, published in The Lancet Neurology journal, in 2021, 3.4 billion people suffered a nervous system condition. Thus, the rising prevalence of neurological disorders is expected to boost the demand for advanced neurological solutions, driving the growth of the neurogenomics market.
Neurogenomics Market Opportunity
Increasing Adoption of Targeted Therapies
Targeted therapies are being increasingly adopted in neurogenomics studies due to several factors, including their ability to target specific cells, their efficacy and safety, and the increasing number of targeted therapies being approved by the FDA. Also, in neurogenomics, targeted therapies can restrict disease progression in the early phases. NGS has a major application in cancer diagnosis and targeted therapies based on biomarkers. The use of targeted therapies is expected to boost the demand for neurogenomics solutions, generating market growth opportunities in the long run.
Neurogenomics Market Trend
The capability to sequence the genes of any organism for clinical and research purposes has transformed public health. Portable handheld sequencing devices are driving future market growth by making sequencing more affordable, user-friendly, and faster, eliminating the need for large clinical laboratory facilities. Real-time sequencing allows researchers and clinicians to access data swiftly and respond promptly. Portable nanopore-based sequencers can sequence an entire genome for under USD 1,000. These devices work by passing the DNA molecule through a nanopore—a small protein embedded in a membrane. As the DNA moves through the nanopore, it connects with an adaptor, initiating an electric current that is recorded and displayed as a graph. Consequently, the increasing adoption of portable sequencers is expected to significantly boost the neurogenomics market.
Neurogenomics Market Analysis: Key Findings
The Next-generation Sequencing (NGS) Segment to Dominate the Neurogenomics Market in 2024
By offering, the neurogenomics market is segmented into NGS, PCR, microarray, and software & services. In 2024, the Next-generation Sequencing (NGS) segment is expected to account for the largest share of 63.9% of the neurogenomics market. This segment’s substantial market share is primarily attributed to the recurring demand for consumables, increasing sequencing-based clinical & research applications of neurogenomics, and the growing preference for sequencing-based diagnostics.
Moreover, the NGS segment is also expected to record the highest CAGR during the forecast period due to the increasing demand for NGS consumables, the higher accuracy of NGS compared to other sequencing technologies, and the increasing number of genomics projects based on sequencing.
The Research Applications Segment to Dominate the Neurogenomics Market in 2024
By application, the neurogenomics market is segmented into research applications and clinical applications. The research applications segment is further segmented into functional studies, target identification, variant discovery, and transcription factor binding analysis. In 2024, the research applications segment is expected to account for the larger share of 61.6% of the neurogenomics market. This segment’s large share is attributed to the extensive use of NGS, PCR, and microarray solutions in research to identify specific genes and their sequences to gain a better understanding of the mechanisms underlying complex neurological diseases such as Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and psychiatric disorders.
Moreover, the research applications segment is expected to record the higher CAGR during the forecast period due to the rising demand for advanced research solutions among laboratories to develop treatments for neurological conditions, the increasing demand for personalized medicine, and research studies to identify specific gene mutations in complex neurological diseases such as Alzheimer’s disease and Parkinson’s disease.
The Pharmaceutical & Biotechnology Companies Segment to Dominate the Neurogenomics Market in 2024
By end user, the neurogenomics market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, and academic & research institutes. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of 44.6% of the neurogenomics market. This segment’s large share is primarily attributed to pharmaceutical & biotechnology companies’ high adoption of advanced technologies for research, the high availability of capital for research, increasing research for drug discovery, and the widening applications of NGS.
However, the academic & research institutes segment is expected to record the highest CAGR during the forecast period due to the rising number of research centers, increasing private & government funding for neurogenomics research, and the increasing utilization of advanced solutions by academic & research institutes.
Geographical Analysis
In 2024, North America is expected to account for the largest share of 47.2% of the neurogenomics market. The growth of this market is primarily attributed to the increasing R&D expenditures in the pharmaceutical & biotechnology sector, the presence of leading sequencing solutions providers in the region, favorable government initiatives for genomics research, growing applications of sequencing-based research, increasing prevalence of neurological disorders, and favorable reimbursement scenario in the region.
Moreover, the market in Asia-Pacific is slated to register the highest CAGR of 17.9% during the forecast period. Countries in the Asia-Pacific region, particularly China and India, are expected to provide significant growth opportunities for vendors in this market. Many nations in this area are intensifying their efforts to improve the healthcare sector, resulting in increased investments aimed at enhancing healthcare accessibility, infrastructure, and drug discovery programs. Additional key factors driving growth in the region include the rising incidence and prevalence of neurological disorders, the growing adoption of advanced diagnostic and therapeutic technologies, and supportive government initiatives for the healthcare sector.
Neurogenomics Market: Key Companies
The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted in the last three to four years. Some of the key players operating in the neurogenomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).
Neurogenomics Industry Overview: Latest Developments from Key Industry Players
- In March 2023, Illumina launched the Illumina Complete Long Read Prep, Human assay, compatible with the Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems. This assay enables access to both long- and short-read data using a single instrument, offering enhanced flexibility for a range of genomic applications.
- In September 2022, Illumina launched the NovaSeq 6000 Dx, the first FDA-registered and CE-marked IVD high-throughput sequencer. This release also included the Illumina Complete Long-Reads, XLEAP-SBS Chemistry, NextSeq 1000/2000 Roadmap, and the NovaSeq X Series (NovaSeq X and NovaSeq X Plus).
- In October 2023, Thermo Fisher Scientific, Inc. (U.S.) acquired Olink Proteomics AB, a Sweden-based company specializing in advanced proteomics discovery and development. Olink operates across the Americas, Europe, and Asia-Pacific, expanding Thermo Fisher's capabilities in the field of proteomics.
- In March 2022, Thermo Fisher Scientific, Inc. (U.S.) launched the Ion Torrent Genexus Dx Integrated Sequencer, an automated Next-generation Sequencing (NGS) platform capable of delivering results within a single day.
Neurogenomics Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
~250 |
|
Format |
|
|
Forecast Period |
2024–2031 |
|
Base Year |
2023 |
|
CAGR (Value) |
16.6% |
|
Market Size (Value) |
$4.68 Billion by 2031 |
|
Segments Covered |
By Offering
By Application
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America and Middle East & Africa |
|
Key Companies Profiled |
Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China) |
Key questions answered in the neurogenomics market report:
The neurogenomics market study focuses on market assessment and opportunity analysis based on the sales of neurogenomics products across various market segments. The report also includes a competitive analysis based on the leading market players’ product portfolios and key growth strategies adopted in the last 3–4 years. The report also provides insights on factors impacting market growth, regulatory analysis, pricing analysis, and Porter’s five forces analysis.
The neurogenomics market is projected to reach $4.68 billion by 2031, at a CAGR of 16.6% during the forecast period.
In 2024, the next-generation sequencing (NGS) segment is expected to hold the major share of the neurogenomics market.
The research applications segment is expected to witness the fastest growth during the forecast period 2024–2031.
The growth of the neurogenomics market is driven by the declining costs of sequencing, the increasing prevalence of neurological disorders, the growing utilization of advanced sequencing technologies in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for gene sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of neurological disorders, technological advancements in neurogenomics products, and government initiatives promoting the use of sequencing in clinical & research applications.
Furthermore, the increasing adoption of targeted therapies, emerging economies, and rising awareness regarding neurological disorders are expected to generate growth opportunities for market stakeholders.
The key players operating in the neurogenomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).
The countries like China and India are projected to offer significant growth opportunities for the vendors in this market. The growth of this regional market is attributed to the accelerated economic growth in many countries within the region, leading to increased government focus on improving the healthcare sector. This has resulted in high investments to enhance the accessibility of healthcare services, improve healthcare infrastructure, and support for drug discovery and genome mapping programs.
1. Introduction
1.1. Market Definition and Scope
1.2. Market Ecosystem
1.3. Currency & Limitation
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Data Collection and Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Market Share Analysis
2.3.3. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Impact Analysis of Market Dynamics
4.2.2. Factor Analysis
4.3. Pricing Analysis
4.4. Technology Trends
4.4.1. Development of Portable Sequencing Technologies
4.5. Regulatory Analysis
4.5.1. Neurogenomics Instruments & Consumables
4.5.1.1. North America
4.5.1.1.1. U.S.
4.5.1.1.2. Canada
4.5.1.2. Europe
4.5.1.3. Asia-Pacific
4.5.1.3.1. China
4.5.1.3.2. Japan
4.5.1.3.3. India
4.5.1.4. Latin America
4.5.1.5. Middle East
4.5.2. Neurogenomics Software
4.6. Porter’s Five Forces Analysis
5. Neurogenomics Market Assessment—by Offering
5.1. Overview
5.2. Next-generation Sequencing (NGS)
5.2.1. Kits & Reagents
5.2.1.1. Library Preparation & Target Enrichment Kits & Reagents
5.2.1.2. DNA Extraction and Amplification Kits & Reagents
5.2.1.3. Quality Control Kits & Reagents
5.2.1.4. Other Kits & Reagents
5.2.2. Systems
5.3. Polymerase Chain Reaction (PCR)
5.3.1. Kits & Reagents
5.3.2. Systems
5.4. Microarray
5.4.1. Kits & Reagents
5.4.1.1. DNA & RNA Microarray Kits & Reagents
5.4.1.2. Protein Microarray Kits & Reagents
5.4.1.3. Tissue Microarray Kits & Reagents
5.4.2. Readers & Scanners
5.5. Software & Services
6. Neurogenomics Market Assessment—by Application
6.1. Overview
6.2. Research Applications
6.2.1. Target Identification
6.2.2. Functional Studies
6.2.3. Variant Discovery
6.2.4. Transcription Factor Binding Analysis
6.3. Clinical Applications
7. Neurogenomics Market Assessment—by End User
7.1. Overview
7.2. Pharmaceutical & Biotechnology Companies
7.3. Academic & Research Institutes
7.4. Hospitals & Diagnostic Laboratories
8. Neurogenomics Market Assessment—by Geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe (RoE)
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America
8.6. Middle East & Africa
9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis (2023)
9.5.1. Illumina, Inc. (U.S.)
9.5.2. Thermo Fisher Scientific Inc. (U.S.)
9.5.3. F. Hoffmann-La Roche Ltd (Switzerland)
10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
10.1. Illumina, Inc.
10.2. Thermo Fisher Scientific Inc.
10.3. F. Hoffmann-La Roche Ltd
10.4. Agilent Technologies, Inc.
10.5. MGI Tech Co., Ltd.
10.6. QIAGEN N.V.
10.7. Revvity, Inc.
10.8. Pacific Biosciences of California Inc.
10.9. Danaher Corporation
10.10. Oxford Nanopore Technologies Plc.
(Note: *SWOT Analysis of the top 5 companies will be provided)
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Tables
Table 1 Global Estimated Number of New Brain & Central Nervous System Cancer Cases, by Region, 2020 Vs. 2045
Table 2 Sequencing Kits & Reagents/Consumables: Pricing
Table 3 Sequencing Instruments: Product Description & Pricing
Table 4 PCR Consumables & Instruments: Pricing
Table 5 Portable Sequencers VS. Benchtop Sequencers: Key Differences
Table 6 Regulatory Authorities Governing In Vitro Diagnostics & Neurogenomics Solutions, by Country/Region
Table 7 Neurogenomics Software: Standards and Compliance Guidelines
Table 8 Global Neurogenomics Market, by offering, 2022–2031 (USD Million)
Table 9 Global Next-generation Sequencing (NGS) Market for Neurogenomics, by Product, 2022–2031 (USD Million)
Table 10 Global Next-generation Sequencing (NGS) Market for Neurogenomics, by Country/Region, 2022–2031 (USD Million)
Table 11 Global Next-generation Sequencing (NGS) Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 12 Global Next-generation Sequencing (NGS) Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Global Library Preparation and Target Enrichment Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 14 Global DNA Extraction & Amplification Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Quality Control Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Other Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 17 Global NGS Systems Market, by Country/Region, 2022–2031 (USD Million)
Table 18 Global Polymerase Chain Reaction (PCR) Market for Neurogenomics, by Type, 2022–2031 (USD Million)
Table 19 Global Polymerase Chain Reaction (PCR) Market for Neurogenomics, by Country/Region, 2022–2031 (USD Million)
Table 20 Global PCR Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 21 Global PCR Systems Market, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Microarrays Market for Neurogenomics, by Type, 2022–2031 (USD Million)
Table 23 Global Microarrays Market for Neurogenomics, by Country/Region, 2022–2031 (USD Million)
Table 24 Global Microarrays Kits & Reagents Market, by Type, 2022–2031 (USD MILLION)
Table 25 Global Microarrays Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 26 Global DNA & RNA Microarray Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Protein Microarray Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 28 Global Tissue Microarray Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Microarray Readers & Scanners Market, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Neurogenomics Software & Services Market, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 32 Global Neurogenomics Market for Research Applications, by Type, 2022–2031 (USD Million)
Table 33 Global Neurogenomics Market for Target Identification, 2022-2031 (USD Million)
Table 34 Global Neurogenomics Market for Functional Studies, 2022-2031 (USD MILLION)
Table 35 Global Neurogenomics Market for Variant Discovery, 2022-2031 (USD MILLION)
Table 36 Global Neurogenomics Market for Transcription Factor Binding Analysis, 2022-2031 (USD MILLION)
Table 37 Global Neurogenomics Market for Clinical Applications, 2022-2031 (USD MILLION)
Table 38 Global Neurogenomics Market, By End User, 2022–2031 (USD MILLION)
Table 39 Pharmaceutical Spending in Major Countries
Table 40 Global Neurogenomics Market for Pharmaceutical & Biotechnology Companies, 2022-2031 (USD Million)
Table 41 Global Neurogenomics Market for Academic & Research Institutes, 2022-2031 (USD Million)
Table 42 Global Neurogenomics Market for Hospitals & Diagnostic Laboratories, 2022-2031 (USD MILLION)
Table 43 Global Neurogenomics Market, by Country/Region, 2022–2031 (USD Million)
Table 44 North America: Neurogenomics Market, by Country, 2022-2031 (USD Million)
Table 45 North America: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 46 North America: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 47 North America: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 48 North America: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 49 North America: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 50 North America: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 51 North America: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 52 North America: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 53 North America: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 54 U.S.: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 55 U.S.: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 56 U.S.: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 57 U.S.: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 58 U.S.: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 59 U.S.: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 60 U.S.: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 61 U.S.: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 62 U.S.: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 63 Canada: Neurogenomics Market, by offering, 2022–2031 (USD Million)
Table 64 Canada: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 65 Canada: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 66 Canada: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 67 Canada: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 68 Canada: Neurogenomics Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 69 Canada: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 70 Canada: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 71 Canada: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 72 Europe: Neurogenomics Market, by Country/Region, 2022-2031 (USD Million)
Table 73 Europe: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 74 Europe: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 75 Europe: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 76 Europe: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 77 Europe: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 78 Europe: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 79 Europe: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 80 Europe: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 81 Europe: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 82 Germany: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 83 Germany: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 84 Germany: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 85 Germany: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 86 Germany: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 87 Germany: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 88 Germany: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 89 Germany: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 90 Germany: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 91 France: Deaths due to Neuropsychiatric Conditions, by Sex and Age Group (2020)
Table 92 France: Neurogenomics Market, by offering, 2022–2031 (USD Million)
Table 93 France: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 94 France: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 95 France: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 96 France: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 97 France: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 98 France: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 99 France: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 100 France: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 101 Emergency In-Patient Hospital Admissions With a Mention Of Neurological Emergency Codes in England Among Adults Aged 18 Years and Over (2019–2020)
Table 102 Number of Deaths Registered due to Dementia and Alzheimer’s Disease in Wales and in Regions of England (2019)
Table 103 U.K.: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 104 U.K.: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 105 U.K.: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 106 U.K.: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 107 U.K.: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 108 U.K.: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 109 U.K.: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 110 U.K.: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 111 U.K.: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 112 Italy: Deaths due to Neuropsychiatric Conditions, by Sex and Age Group (2020)
Table 113 Italy: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 114 Italy: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 115 Italy: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 116 Italy: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 117 Italy: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 118 Italy: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 119 Italy: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 120 Italy: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 121 Italy: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 122 Spain: Deaths Due to Neuropsychiatric Conditions, by Sex and Age Group (2021)
Table 123 Spain: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 124 Spain: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 125 Spain: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 126 Spain: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 127 Spain: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 128 Spain: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 129 Spain: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 130 Spain: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 131 Spain: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 132 RoE: Estimated Number Of New Brain And Central Nervous System Cancer Cases, by Country (2022 Vs. 2045)
Table 133 Rest of Europe: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 134 Rest of Europe: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 135 Rest of Europe: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 136 Rest of Europe: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 137 Rest of Europe: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 138 Rest of Europe: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 139 Rest of Europe: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 140 Rest of Europe: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 141 Rest of Europe: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 142 Asia-Pacific: Neurogenomics Market, by Country/Region, 2022-2031 (USD Million)
Table 143 Asia-Pacific: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 144 Asia-Pacific: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 145 Asia-Pacific: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 146 Asia-Pacific: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 147 Asia-Pacific: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 148 Asia-Pacific: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 149 Asia-Pacific: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 150 Asia-Pacific: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 151 Asia-Pacific: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 152 China: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 153 China: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 154 China: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 155 China: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 156 China: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 157 China: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 158 China: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 159 China: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 160 China: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 161 Japan: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 162 Japan: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 163 Japan: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 164 Japan: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 165 Japan: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 166 Japan: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 167 Japan: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 168 Japan: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 169 Japan: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 170 India: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 171 India: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 172 India: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 173 India: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 174 India: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 175 India: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 176 India: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 177 India: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 178 India: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 179 Rest of Asia-Pacific: Estimated Number of New Brain and Central Nervous System Cancer Cases, By Country (2022 VS. 2040)
Table 180 Rest of Asia-Pacific: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 181 Rest of Asia-Pacific: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 182 Rest of Asia-Pacific: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 183 Rest of Asia-Pacific: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 184 Rest of Asia-Pacific: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 185 Rest of Asia-Pacific: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 186 Rest of Asia-Pacific: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 187 Rest of Asia-Pacific: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 188 Rest of Asia-Pacific: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 189 Latin America: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 190 Latin America: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 191 Latin America: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 192 Latin America: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 193 Latin America: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 194 Latin America: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 195 Latin America: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 196 Latin America: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 197 Latin America: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 198 Middle East & Africa: Neurogenomics Market, by Offering, 2022–2031 (USD Million)
Table 199 Middle East & Africa: Next-generation Sequencing Market, by Type, 2022–2031 (USD Million)
Table 200 Middle East & Africa: Next-generation Sequencing Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 201 Middle East & Africa: Polymerase Chain Reaction (PCR) Market, by Type, 2022–2031 (USD Million)
Table 202 Middle East & Africa: Microarrays Market, by Type, 2022–2031 (USD Million)
Table 203 Middle East & Africa: Microarray Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 204 Middle East & Africa: Neurogenomics Market, by Application, 2022–2031 (USD Million)
Table 205 Middle East & Africa: Neurogenomics Market for Research Applications, by Type 2022–2031 (USD Million)
Table 206 Middle East & Africa: Neurogenomics Market, by End User, 2022–2031 (USD Million)
Table 207 Recent Developments, by Company, 2021-2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Neurogenomics Market, By Offering, 2024 VS. 2031 (USD Million)
Figure 8 Global Neurogenomics Market, By Application, 2024 VS. 2031 (USD Million)
Figure 9 Global Neurogenomics Market, By End User, 2024 VS. 2031 (USD Million)
Figure 10 Global Neurogenomics Market: Impact Analysis of Market Drivers, Restraints, Opportunities, and Challenges (2024–2031)
Figure 11 Genome Sequencing Costs, 2016–2024 (USD/Genome)
Figure 12 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 13 U.S.: Percentage Of Personalized Medicine Approvals Among Total FDA Approvals, 2015-2022 (%)
Figure 14 U.S.: Percentage Distribution Of Older Adults With Alzheimer's Dementia, By Age Group, 2024
Figure 15 Deaths due to Neuropsychiatric Conditions, By Country, 2020
Figure 16 Deaths due to Parkinson’s Disease, By Country, 2021
Figure 17 Deaths due to Alzheimer’s And Other Dementias, By Country, 2021
Figure 18 USFDA Regulatory Pathways for IVD Kits
Figure 19 Eu Regulatory Pathway - IVDR 2017/746
Figure 20 China: Medical Device Classification And Premarket Requirements for Neurogenomics Instruments
Figure 21 Porter's Five Forces Analysis
Figure 22 Global Neurogenomics Market, By Offering, 2024 VS. 2031 (USD Million)
Figure 23 Global Neurogenomics Market, By Application, 2024 VS. 2031 (USD Million)
Figure 24 Global Neurogenomics Market, By End User, 2024 VS. 2031 (USD Million)
Figure 25 Global Pharmaceutical R&D Expenditure, 2014–2028 (USD Billion)
Figure 26 Global Neurogenomics Market, By Region, 2024 Vs. 2031 (USD Million)
Figure 27 North America: Per Capita Healthcare Expenditure (2017-2022)
Figure 28 North America: Neurogenomics Market Snapshot
Figure 29 Europe: Pharmaceutical R&D Expenditure Annual Growth Rate (%)
Figure 30 Europe: Neurogenomics Market Snapshot
Figure 31 Italy: Number Of Biotechnology And Biotechnology R&D-Dedicated Firms (2014-2022)
Figure 32 Spain: Pharmaceutical R&D Expenditure, 2018-2022 (USD Million)
Figure 33 Asia-Pacific: Neurogenomics Market Snapshot
Figure 34 Japan: Pharmaceutical Industry R&D Expenditure, 2017-2022 (USD Million)
Figure 35 Number of Active Life Science Companies in Israel (2017-2022)
Figure 36 Israel: Total Number of Life Science Industries, by Sub-Sectors (2021)
Figure 37 Key Growth Strategies Adopted by Leading Players, 2021– 2024
Figure 38 Global Neurogenomics Market: Competitive Benchmarking by Offering
Figure 39 Global Neurogenomics Market: Competitive Benchmarking, by Region
Figure 40 Competitive Dashboard: Global Neurogenomics Market
Figure 41 Global Neurogenomics Market Share Analysis, by Key Players, 2023 (%)
Figure 42 Illumina, Inc.: Financial Snapshot (2023)
Figure 43 Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
Figure 44 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2023)
Figure 45 Agilent Technologies, Inc.: Financial Snapshot (2023)
Figure 46 MGI Tech Co., Ltd.: Financial Snapshot (2023)
Figure 47 QIAGEN N.V: Financial Snapshot (2023)
Figure 48 Revvity, Inc.: Financial Snapshot (2023)
Figure 49 Pacific Biosciences Of California Inc.: Financial Snapshot (2023)
Figure 50 Danaher Corporation: Financial Snapshot (2023)
Figure 51 Oxford Nanopore Technologies Plc.: Financial Snapshot (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
China Neurogenomics Market - Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Oct-2024
